# AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

> **NCT00528645** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer
- Lung Metastases
- Malignant Pleural Effusion
- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** saracatinib

## Key facts

- **NCT ID:** NCT00528645
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-11
- **Final completion:** 2013-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528645, "AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00528645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*